Sightglass is a technology company.
Sightglass has raised $3.0M across 1 funding round.
Sightglass has raised $3.0M in total across 1 funding round.
Sightglass has raised $3.0M in total across 1 funding round.
Sightglass's investors include Base10 Partners, Draper B1, Felipe Navio, Juan Urdiales.
SightGlass Vision is a medical technology company developing innovative spectacle lenses to slow myopia progression in children, addressing the global myopia epidemic through its proprietary Diffusion Optics Technology™. This patent-protected approach uses thousands of micro-dots to scatter light and reduce retinal contrast, backed by a completed three-year pivotal multisite clinical study; the company now operates as a joint venture between CooperCompanies and EssilorLuxottica to accelerate worldwide commercialization.[1]
It serves children at risk of myopia, eye care professionals, and parents, solving the problem of rapid myopia progression—which affects over 50% of children in some regions—by offering a non-invasive, science-based treatment that mimics natural retinal contrast to curb eye elongation.[1]
Founded in 2016, SightGlass Vision emerged from groundbreaking research on the "unique contrast theory" linking retinal contrast to myopia development.[1] The company's backstory centers on novel discoveries in myopia science, leading to the development of its Diffusion Optics Technology spectacle lenses, which underwent rigorous validation through a three-year multisite clinical trial demonstrating efficacy in slowing progression.[1] In a pivotal moment, it became a joint venture of CooperCompanies and EssilorLuxottica, leveraging their global scale for commercialization and expanding the myopia management category.[1]
SightGlass Vision rides the wave of the global myopia epidemic, driven by trends like increased screen time, urbanization, and lifestyle changes affecting over 2.6 billion people worldwide by 2020, projected to reach 50% of the global population by 2050.[1] Timing is critical amid rising parental awareness and regulatory pushes for myopia management; market forces like aging populations and demand for pediatric eye health favor scalable solutions. As a medtech innovator, it influences the ecosystem by validating contrast-based therapies, spurring competition in spectacle lens tech, and partnering with optical giants to mainstream preventive eye care in emerging markets.[1]
SightGlass Vision is poised for explosive growth through its joint venture, with commercialization ramping up to capture the multibillion-dollar myopia management market. Trends like AI-driven personalized optics and tele-optometry will amplify its reach, while expanding clinical data could solidify it as the gold standard. Its influence may evolve from pioneer to category leader, transforming children's vision health globally and tying back to its mission of curbing an epidemic through science-backed innovation.[1]
Sightglass has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $3.0M Seed | Base10 Partners, Draper B1, Felipe Navio, Juan Urdiales |